Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
April 29 2017 - 1:31AM
Mechelen, Belgium; 29 April 2017, 7.30 CET
-Galapagos NV (Euronext & NASDAQ: GLPG) announces
presentation of pre-clinical pharmacology data with GLPG1972 at the
Osteoarthritis Research Society International (OARSI) annual
meeting today in Las Vegas, USA.
Galapagos and collaboration partner Servier are
developing a potential disease-modifying oral therapy for
osteoarthritis with GLPG1972.
Galapagos today discloses that GLPG1972 is a
potent and highly selective inhibitor of ADAMTS-5, a
well-established target in the literature for osteoarthritis.
ADAMTS-5 is a key enzyme involved in cartilage breakdown (Larkin
2015). At the OARSI 2017 World Congress, Galapagos presents
pre-clinical pharmacology data with GLPG1972 showing cartilage
protection in both rodent and human explant assays.
Disease-modifying activity with GLPG1972 in the gold-standard,
destabilization of the medial meniscus (DMM) rodent model will also
be presented.
Galapagos previously announced that a Phase 1
study in healthy human volunteers demonstrated favorable safety and
PK profiles of GLPG1972, and up to 60% reduction in a cartilage
breakdown biomarker within two weeks of treatment. This biomarker
is serum ARGS-neoepitope, which is formed from cartilage through
ADAMTS-5 and thus serves as a biomarker for target engagement.
"Osteoarthritis is a disease with very limited
treatment options, and none which actually addresses the cause of
the disease. By inhibiting ADAMTS-5, for which the literature
evidence is growing, GLPG1972 could play a central role
in osteoarthritis," said Dr Piet Wigerinck, Chief Scientific
Officer of Galapagos. "We are eager to see if we can repeat in
patients the same impact on cartilage breakdown biomarker
ARGS-neoepitope as we saw in healthy volunteers."
In July 2010, Servier and Galapagos announced
their alliance to develop innnovative oral medicines for the
treatment of osteoarthritis. Galapagos is responsible for the
discovery and development of new candidate drugs against novel
targets, and Servier has an exclusive option to license these
candidates after the completion of the Phase 1 trial and Phase 2A
enabling activities. Under this agreement, Galapagos is eligible to
receive up to €290 million in success-based milestones, plus
royalties on sales.
Galapagos plans to initiate a Phase 1b study in
osteoarthritis patients in the United States this quarter.
Galapagos has the full US commercial rights in the osteoarthritis
collaboration with Servier.
Presentation title: "GLPG1972: A POTENT, SELECTIVE,
ORALLY AVAILABLE ADAMTS-5 INHIBITOR FOR THE TREATMENT OF
OA "OARSI Session: Concurrent Session 8 -
OA Treatments Presentation Time: today at
11:55 AM - 12:05 PM MDT
About GalapagosGalapagos (Euronext & NASDAQ: GLPG) is
a clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action. Our pipeline comprises Phase 3, Phase 2, Phase 1,
pre-clinical, and discovery programs in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We
have discovered and developed filgotinib: in collaboration with
Gilead we aim to bring this JAK1-selective inhibitor for
inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 530
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& Corporate Communications |
Director
Communications |
+1 781
460 1784 Paul van der HorstDirector IR & Business
Development+31 6 53 725 199 |
+31 6 53 591
999communications@glpg.com |
ir@glpg.com |
|
Forward-looking statementsThis release may contain
forward-looking statements, including statements regarding
Galapagos' strategic ambitions, the mechanism of action and profile
of GLPG1972, the anticipated timing of clinical studies with
GLPG1972 and the progression and results of such studies. Galapagos
cautions the reader that forward-looking statements are not
guarantees of future performance. Forward-looking statements
involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition and
liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or
achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos' results, performance,
financial condition and liquidity, and the development of the
industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. Among the factors that may
result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from the ongoing and planned clinical research
programs may not support registration or further development of
GLPG1972 due to safety, efficacy or other reasons), Galapagos'
reliance on collaborations with third parties (including its
collaboration partner for GLPG1972, Servier), and estimating the
commercial potential of Galapagos' product candidates. A further
list and description of these risks, uncertainties and other risks
can be found in Galapagos' Securities and Exchange Commission (SEC)
filings and reports, including in Galapagos' most recent annual
report on form 20-F filed with the SEC and subsequent filings and
reports filed by Galapagos with the SEC. Given these uncertainties,
the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based or
that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements, unless
specifically required by law or regulation.
Galapagos (EU:GLPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2023 to Sep 2024